Ad is loading...
HAE
Price
$85.60
Change
+$0.17 (+0.20%)
Updated
Nov 22, 03:22 PM (EDT)
81 days until earnings call
XRAY
Price
$18.81
Change
+$0.17 (+0.91%)
Updated
Nov 22, 03:41 PM (EDT)
96 days until earnings call
Ad is loading...

HAE vs XRAY

Header iconHAE vs XRAY Comparison
Open Charts HAE vs XRAYBanner chart's image
Haemonetics
Price$85.60
Change+$0.17 (+0.20%)
Volume$400
CapitalizationN/A
DENTSPLY SIRONA
Price$18.81
Change+$0.17 (+0.91%)
Volume$2.15K
CapitalizationN/A
HAE vs XRAY Comparison Chart
Loading...
HAE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
HAE vs. XRAY commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HAE is a StrongSell and XRAY is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (HAE: $85.43 vs. XRAY: $18.64)
Brand notoriety: HAE and XRAY are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: HAE: 89% vs. XRAY: 52%
Market capitalization -- HAE: $4.33B vs. XRAY: $6.69B
HAE [@Medical Specialties] is valued at $4.33B. XRAY’s [@Medical Specialties] market capitalization is $6.69B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HAE’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • HAE’s FA Score: 0 green, 5 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, HAE is a better buy in the long-term than XRAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HAE’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 5 bullish TA indicator(s).

  • HAE’s TA Score: 5 bullish, 5 bearish.
  • XRAY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, XRAY is a better buy in the short-term than HAE.

Price Growth

HAE (@Medical Specialties) experienced а -5.86% price change this week, while XRAY (@Medical Specialties) price change was +4.31% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.22%. For the same industry, the average monthly price growth was +0.99%, and the average quarterly price growth was -2.23%.

Reported Earning Dates

HAE is expected to report earnings on Feb 11, 2025.

XRAY is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Medical Specialties (+3.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XRAY($6.69B) has a higher market cap than HAE($4.34B). HAE has higher P/E ratio than XRAY: HAE (34.47) vs XRAY (19.23). HAE YTD gains are higher at: -0.094 vs. XRAY (-46.710). HAE has higher annual earnings (EBITDA): 264M vs. XRAY (249M). XRAY has more cash in the bank: 334M vs. HAE (194M). HAE has less debt than XRAY: HAE (871M) vs XRAY (2.3B). XRAY has higher revenues than HAE: XRAY (3.97B) vs HAE (1.27B).
HAEXRAYHAE / XRAY
Capitalization4.34B6.69B65%
EBITDA264M249M106%
Gain YTD-0.094-46.7100%
P/E Ratio34.4719.23179%
Revenue1.27B3.97B32%
Total Cash194M334M58%
Total Debt871M2.3B38%
FUNDAMENTALS RATINGS
HAE vs XRAY: Fundamental Ratings
HAE
XRAY
OUTLOOK RATING
1..100
165
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5893
PRICE GROWTH RATING
1..100
4665
P/E GROWTH RATING
1..100
5690
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for HAE (75). This means that XRAY’s stock grew significantly faster than HAE’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HAE (100). This means that XRAY’s stock grew similarly to HAE’s over the last 12 months.

HAE's SMR Rating (58) in the Medical Specialties industry is somewhat better than the same rating for XRAY (93). This means that HAE’s stock grew somewhat faster than XRAY’s over the last 12 months.

HAE's Price Growth Rating (46) in the Medical Specialties industry is in the same range as XRAY (65). This means that HAE’s stock grew similarly to XRAY’s over the last 12 months.

HAE's P/E Growth Rating (56) in the Medical Specialties industry is somewhat better than the same rating for XRAY (90). This means that HAE’s stock grew somewhat faster than XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HAEXRAY
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
50%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
57%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
59%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 4 days ago
57%
Declines
ODDS (%)
Bearish Trend 4 days ago
63%
Bearish Trend about 1 month ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
49%
Aroon
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
HAE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GREK39.090.44
+1.14%
Global X MSCI Greece ETF
NACP42.620.20
+0.46%
Impact Shares NAACP Minority Empwrmt ETF
NWLG33.56N/A
N/A
Nuveen Winslow Large-Cap Growth ESG ETF
VUSB49.71-0.01
-0.02%
Vanguard Ultra-Short Bond ETF
ARGT81.47-0.03
-0.04%
Global X MSCI Argentina ETF

HAE and

Correlation & Price change

A.I.dvisor indicates that over the last year, HAE has been loosely correlated with OM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HAE jumps, then OM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HAE
1D Price
Change %
HAE100%
+0.60%
OM - HAE
44%
Loosely correlated
+4.78%
GH - HAE
37%
Loosely correlated
+0.98%
CRL - HAE
32%
Poorly correlated
+3.35%
XRAY - HAE
29%
Poorly correlated
+0.65%
A - HAE
28%
Poorly correlated
+2.71%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with KIDS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then KIDS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
+0.65%
KIDS - XRAY
45%
Loosely correlated
+3.80%
HBIO - XRAY
44%
Loosely correlated
N/A
STE - XRAY
44%
Loosely correlated
+1.66%
ZBH - XRAY
43%
Loosely correlated
-0.80%
NVST - XRAY
43%
Loosely correlated
+5.01%
More